Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT06349980
Ignite Creation Date: 2024-05-06 @ 8:21 PM
Last Modification Date: 2024-10-26 @ 3:26 PM
Study NCT ID: NCT06349980
Protocol Section: NCT06349980
Start Identification Module Data
Expand Identification Module Data
Brief Title: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma Patients
Official Title: A Randomized Double-blind Multi-center Phase II Study to Evaluate the Anti-tumor Efficacy Safety and Tolerability of HLX53 an Anti-TIGIT Fc Fusion Protein Combined With Serplulimab Injection HLX10 a Recombinant Anti-PD-1 Antibody and HLX04 a Biosimilar to Bevacizumab Compared to Placebo Serplulimab HLX04 in Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma Patients
Acronym: None
Organization: Shanghai Henlius Biotech
Organization Class: INDUSTRY
Organization Study ID: HLX53-HCC201
Start Status Module Data
Status Verified Date: 2024-04
Overall Status: NOT_YET_RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Shanghai Henlius Biotech
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Shanghai Henlius Biotech
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload